The Pharma Data

DECEMBER 12, 2020

It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. The complement cascade is pivotal to the innate immune system. Morgan Stanley & Co. Morgan Cazenove) (“J.P.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

OCTOBER 29, 2020

ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. Enrollment is underway in two parallel Phase 3 studies – one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease. Eidos is currently evaluating AG10 in a Phase 3 study in the U.S.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Disclaimer. Source link: [link].

RNA 52

RNA Trials Production Containment 52

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 million and $8.9

Sales 40

Sales Production Marketing Cardiology 40

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. Disclosure Notice: The information contained in this release is as of September 15, 2020. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98